IP Library Granted Patent US 8,987,312
Granted Patent B2
US 8,987,312 · App. 13/002,905 · Granted Mar 24, 2015

Alpha-keto heterocycles as FAAH inhibitors

Inventor: Dale L. Boger (La Jolla, CA)
Assignee: The Scripps Research Institute
A61K31/13A61K9/20A61K9/4866A61K31/18A61K31/395C07D401/04C07D403/04C07D413/04C07D417/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,987,312
App. No.
13/002,905
Granted
Mar 24, 2015
Kind
B2
Abstract

The invention provides a series of -αketoheterocyclic compounds, for example, compounds of formula (I). The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further provides methods of making compounds of formula (I), useful intermediates for the preparation of compounds of formula (I), and methods of using compounds of formula (I) and compositions thereof.

Claims (30)

1. A compound of formula I:

wherein

R 1 is one of the following:

(a) furanyl, thiophenyl, or pyridinyl,

(b) —CO 2 (C 1 -C 8 )alkyl or —CO 2 H, or

(c) furanyl, thiophenyl, or pyridinyl, each of which substituted with one or more substituents selected from the group consisting of alkyl, halo, alkoxycarbonyl, carboxy, and cyano;

Het is thiazole;

linker is a (C 1 -C 20 )alkyl chain;

Ar is phenyl;

n is 1;

R 2 is H,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein R 1 is 2-pyridyl, 2-furyl, or 2-thiophenyl.

3. The compound of claim 1 wherein R 1 is —CO 2 H or —CO 2 Me.

4. The compound of claim 1 wherein the linker is a (C 1 -C 8 )alkyl.

5. A composition comprising a compound of claim 1 and a diluent or carrier.

6. A compound of formula (I) of claim 1 selected from

7-Phenyl-1-(5-(pyridin-2-yl)-thiazol-2-yl)-heptan-1-one;

1-(5-(Furan-2-yl)-thiazol-2-yl)-7-phenylheptan-1-one;

7-Phenyl-1-(5-(thiophen-2-yl)-thiazol-2-yl)-heptan-1-one;

Methyl 6-(2-(7-Phenylheptanoyl)-thiazol-5-yl)-picolinate;

6-(2-(7-Phenylheptanoyl)thiazol-5-yl)-picolinic acid;

7-Phenyl-1-(5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl)-heptan-1-one;

1-(5-(Furan-2-yl)-1,3,4-thiadiazol-2-yl)-7-phenylheptan-1-one;

7-Phenyl-1-(5-(thiophen-2-yl)-1,3,4-thiadiazol-2-yl)-heptan-1-one;

1-(5-(6-Bromopyridin-2-yl)-1,3,4-thiadiazol-2-yl)-7-phenylheptan-1-one;

Methyl 6-(5-(7-Phenylheptanoyl)-1,3,4-thiadiazol-2-yl)-picolinate;

6-(5-(7-Phenylheptanoyl)-1,3,4-thiadiazol-2-yl)-picolinic acid;

Methyl 5-(7-Phenylheptanoyl)-1,3,4-thiadiazole-2-carboxylate;

or a salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2011
From: BOGER, DALE L.
To: SCRIPPS RESEARCH INSTITUTE, THE
Reel/Frame 026375/0996 →
CONFIRMATORY LICENSE Recorded Mar 24, 2011
From: THE SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026010/0853 →
Continuity (2)
Provisional Application 61079271 · Jul 9, 2008
Related Publication 20110183947A1 · Jul 28, 2011